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Abstract
The interplay between the innate immune system restriction factor APOBEC3G and the HIV protein Vif is a key host-
retrovirus interaction. APOBEC3G can counteract HIV infection in at least two ways: by inducing lethal mutations on the viral
cDNA; and by blocking steps in reverse transcription and viral integration into the host genome. HIV-Vif blocks these
antiviral functions of APOBEC3G by impeding its encapsulation. Nonetheless, it has been shown that overexpression of
APOBEC3G, or interfering with APOBEC3G-Vif binding, can efficiently block in vitro HIV replication. Some clinical studies
have also suggested that high levels of APOBEC3G expression in HIV patients are correlated with increased CD4+ T cell
count and low levels of viral load; however, other studies have reported contradictory results and challenged this
observation. Stem cell therapy to replace a patient’s immune cells with cells that are more HIV-resistant is a promising
approach. Pre-implantation gene transfection of these stem cells can augment the HIV-resistance of progeny CD4+ T cells.
As a protein, APOBEC3G has the advantage that it can be genetically encoded, while small molecules cannot. We have
developed a mathematical model to quantitatively study the effects on in vivo HIV replication of therapeutic delivery of
CD34+ stem cells transfected to overexpress APOBEC3G. Our model suggests that stem cell therapy resulting in a high
fraction of APOBEC3G-overexpressing CD4+ T cells can effectively inhibit in vivo HIV replication. We extended our model to
simulate the combination of APOBEC3G therapy with other biological activities, to estimate the likelihood of improved
outcomes.
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Introduction
The innate immune system is a key line of defense against
human immunodeficiency virus type 1 (HIV-1), reducing viral
replication and protecting neighboring cells from infection. Key in
this battle between host and virus are cytosolic host cell proteins
with antiretroviral activities, termed restriction factors. The
apolipoprotein B (apo B) messenger RNA (mRNA)-editing,
catalytic polypeptide-like 3 (APOBEC3) family of proteins are
known to be potent restriction factors and to counteract infection
by HIV-1 (reviewed in [1–9]). While the seven APOBEC3
proteins have varying levels of potency, in in vitro tissue culture
APOBEC3G (A3G) exhibits the highest activity against HIV-1
that lacks the viral infectivity factor (vif) gene [1,2].
Ten years after its discovery [10], the antiviral functions of A3G
are still the subject of active research. Hypermutation of HIV
cDNA via the deaminase functionality of A3G is thought to be the
most important A3G mechanism against HIV-1. A3G can induce
up to 10% guanosine to adenosine (G-to-A) mutations into viral
reverse transcripts [2,6,11], by deaminating cytidine (C) to uridine
(U) on the minus strand [10,12–15]. This high mutational
frequency can destroy viral genome integrity, resulting in
production of noninfectious virions. Several groups have suggested
that deaminase-independent antiviral activities of A3G also play a
role in blocking HIV-1 replication. These include inhibiting
several steps during viral reverse transcription and integration [16–
26]. Note that it is the A3G from the cell in which the virus is
made that binds to viral mRNA and gets encapsulated in progeny
virions. It is only after the virus is released and infects another cell
that the encapsulated A3G exerts both its deaminase-dependent
and -independent activities.
As mentioned earlier, HIV-1 has developed the ability to evade
the antiviral activities of A3G through the expression of Vif, a
viral-encoded protein [27–29]. Vif binds to A3G [30–33] and
exerts multiple counter-mechanisms to block encapsulation of
A3G into virions. One mechanism is Vif-induced degradation of
A3G where Vif recruits an E3 ubiquitin ligase complex and
facilitates degradation of A3G through the proteasomal pathway
[10,34–40]. It has also been suggested that Vif directly impedes
encapsulation of A3G into virions [30,37,41].
Fig. 1 shows a basic diagram of HIV infection as well as
interactions between HIV-1 and A3G in HIV producing and
newly infected CD4+ T cells. We previously developed a multi-
scale computational model of HIV infection in in vitro T cell
culture, consisting of intracellular, cellular and extracellular events
[42]. One of the predictions of that model was that overexpression
of A3G or of a mutated form lacking the Vif-binding site (termed
A3GDVif) [43,44] can effectively stop in vitro HIV replication. This
prediction was in agreement with a number of studies in which
elevated levels of A3G expression resulted in A3G overcoming the
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effects of Vif [10,41,45,46]. The model also predicted that the
degradation of A3G by Vif is not a crucial step in HIV
pathogenesis; instead it is the binding of A3G to Vif that is the
key step and must be targeted to improve A3G efficacy [42]. Our
goal in this study is to transpose our validated model of A3G-Vif
interactions from simulations of in vitro cell culture to simulations
of in vivo HIV infection and treatment.
Targeting the A3G-Vif pathway may provide a new class of
antiretroviral therapy; however, some clinical studies have
provided controversial results [47–58], and to date, these studies
on the effects of A3G on HIV disease progression have not
covered large numbers of individuals. In a 2005 study, Jin et al.
found that in a group of 25 untreated HIV+ patients, A3G mRNA
levels were negatively correlated with HIV viral loads and were
significantly associated with CD4+ T cell counts [47]. Results
reported by two other research groups found that subjects with
high G-to-A hypermutation had lower plasma HIV RNA levels
and higher CD4+ T cell counts; however A3G mRNA levels were
not directly measured [48,49]. Interestingly, the association of
reduced plasma HIV RNA levels with hypermutation was
considerably greater than association of reduced plasma HIV
RNA levels with the CCR5D32 allele [48]. Ulenga et al. found that
the expression levels of A3G were correlated with the levels of
hypermutation in the vif and env regions, but not in the gag region
of the virus genome. On the other hand, their study suggested no
correlation between plasma viral loads and the levels of
hypermutation in the vif, env, and gag regions [50]. In contrast,
another study published by the same group found that the
expression levels of A3G mRNA in patients with low viral set point
were significantly higher than those of patients with high viral set
point [51]. While other clinical studies have also shown the ability
of A3G to modulate in vivo HIV infection [52,53], some groups
have not been able to reproduce the same results [54–58].
Therefore, further investigation on the role of A3G in HIV disease
progression would greatly benefit the field.
In addition to the A3G-Vif axis being a potential therapeutic
anti-HIV approach, recent studies have suggested that A3G may
also be used as a preventive strategy against HIV-1. Biasin et al.
demonstrated that HIV-exposed seronegative subjects had signif-
icantly increased A3G mRNA and protein expressions compared
to HIV-seropositive patients and healthy control individuals [59].
This higher expression was associated with lower susceptibility of
cells to in vitro HIV infection [59]. Similar results were reported in
a 2009 study by Vázquez-Pérez et al., where the average A3G
mRNA expression was over 2-fold higher in exposed uninfected
subjects that those of healthy control individuals [52].
Replacing HIV-susceptible cells with more resistant cells, for
example, by using gene therapy with or without hematopoietic
stem cell transplantation, is proposed as one possible way to
achieve a functional cure for HIV infection [60,61]. A
functional cure, as opposed to eradicative cure, is a stable
suppression of HIV-1 replication in the absence of highly active
antiretroviral therapy [62]. Current advances in the use of gene
therapy methods for HIV-1 treatment [63–68] and one report
of successful eradication of virus in an infected individual [69–
71] suggest that transfection of CD34+ stem cells with a gene
encoding wild type (WT) A3G or its variants will be feasible in
the future [1,72]. Considering that clinical effects of A3G are
not clear, we aim to predict the effects of A3G-augmented stem
cell therapy (A3G-SCT) on modulation of in vivo HIV replica-
Figure 1. HIV life cycle. Mechanism of HIV infection including viral entry, reverse transcription, integration of viral DNA, virion assembly and release
of viral particles is schematically shown. A3G, a host protein and a restriction factor, binds to viral mRNA and gets encapsulated into the viral capsid. If
viruses carrying A3G infect other cells, the packaged A3G will exert several antiviral activities, which include inducing G-to-A mutations into viral
reverse transcripts by deaminating C to U on the minus strand, blocking multiple steps in reverse transcription and causing integration defects. Vif, a
viral protein, binds to A3G and inhibits encapsulation of A3G into virions by facilitating degradation of this protein through the proteasomal pathway.
doi:10.1371/journal.pone.0063984.g001
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tion and to quantify some critical hurdles using mathematical
models and simulations.
Our central question is, can the transplantation of stem cells
transfected with A3G or its variants halt in vivo HIV replication? If
yes, what percentage of the cells must be transfected and how
much inhibitory potency (A3G overexpression), is required?
In this paper, we build upon the basic model of in vivo HIV
infection [73–78] and extend it using the results of our multi-scale
model of A3G-Vif interactions (Fig. 1 and [42]). Other relevant
biological phenomena such as accelerated cell death are also
included into extended models in order to study their impacts on
the performance of A3G-SCT. Then we analyze the models at
steady state to evaluate the likely long-term effects of this
treatment.
Models
In this section, we briefly introduce the basic model of in vivo
HIV infection [73–78] and then extend it into models capable of
studying the effects of A3G-augmented stem cell therapy (A3G-
SCT) on virus replication in the body. All variables are capitalized
and represent concentrations of different cell types or viruses with
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In this model, free viruses infect susceptible CD4+ T cells
and give rise to infected cells (Fig. 2A). T, I and V represent the
concentration of uninfected CD4+ T cells, infected cells, and
free virus, respectively. The rate of infection is proportional to
the concentration of free virus and T cells and is equal to kVT
where k is the infectivity rate constant with units ml6day21. The
infected cells produce and release on average N new free virions
per day. Uninfected cells are produced in the thymus at a
constant rate, l cells/(ml6day). Uninfected and infected cells die
at the rates dT and dI , respectively. Free viruses are cleared at a
rate of dV . The last three parameters have units of day
21. The
values for these parameters in our models are consistent with
previously published results [42,73,77,79–86] and are given in
Table 1.
Prior to infection, there are zero viruses and zero infected cells;
Uninfected cells are at the steady state value balancing production
and death, i.e., . After infection occurs (in the model, this is
represented by an initial input of viruses), the system moves





Where I~0 suggests that virus has been eradicated from the
body while I~(lkN{dI dT dV )=dI kN implies that virus has
grown and established an infection in the body. The latter
equilibrium point is only stable if the concentration of infected cells
is greater than zero, meaning that the numerator in equation (2)





where R0 is known as the basic reproductive ratio, describing
the average number of secondary infected cells arising from
each primary infected cell when almost all cells are uninfected.
Therefore, if the reproductive ratio takes values greater than
one, HIV infection spreads through the body; while values less
than one imply that the infection dies out and the virus
becomes eradicated. In a study by Little et al., the basic
reproductive ratio of 4 patients was estimated in the range of
5.2 to 9.1 with a mean value of 7.1 [87]. Stafford et al. analyzed
10 patients and found a median of 5.7, with a range between
2.8 and 11.0 for R0 [86]. Using a slightly different model, one
group found R0 estimates ranging from 7.4 to 34, with a mean
value of 19.3 [87] and recently another group obtained an
estimated mean of 8.6 for R0 with 75% of 47 patients having R0
values less than 11 and two infected individuals having R0
values greater than 20 (highest value = 26.4) [88]. The goal of
any strategy for HIV treatment or cure must be to reduce R0 to
values less than one. Fig. 2B shows the impact of decreasing k
and hence reducing R0 on the system.
Model I: The Basic HIV Model for A3G-Augmented Cells
In the first extension of the basic model of HIV infection, we
assume all the stem cells are transfected with A3G and hence all
the progeny CD4+ T cells in the body overexpress A3G in
addition to their biological expression of A3G; we term these A3G-
augmented cells as opposed to WT cells. When these cells are
infected by viruses, A3G overexpressed in cells overcomes Vif and
gets encapsulated in some of the budded viruses, meaning that
infected cells produce two types of virus: those that carry A3G,
hence called A3G(+) viruses, and those viruses that do not, dubbed
A3G(2) viruses; the ratio of A3G(2) to total released viruses is an
important factor in the model. Cells infected by A3G(+) viruses
produce fewer virions compared to cells infected by A3G(2)
viruses, because the A3G carried in A3G(+) viruses affects viral
production by inhibiting several steps of the HIV life cycle inside
the infected cell. The model of HIV infection for A3G-augmented
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Where T (z) represents the concentration of A3G-augmented
CD4+ T cells and V({) and V(z) denote the concentration of
A3G(2) and A3G(+) viruses, respectively. I (z)({) and I
(z)
(z) represent
the concentration of A3G-augmented cells infected by A3G(2)
and A3G(+) viruses, respectively.
As mentioned earlier, infected A3G-augmented cells release
both A3G(2) and A3G(+) viruses. In the model, parameter p(z)
taking values between 0 and 1, denotes the fraction of A3G(2)
viruses released from an infected cell and therefore is termed A3G-
free virus release ratio. The superscript on p(z) denotes that it is a
property of T (z). As seen in equations (4d) and (4e), for every N
viruses that are produced p(z)N are A3G(2) viruses whereas (1-
p(z))N are A3G(+) viruses. The value of p(z) depends on the
concentrations of Vif and of A3G expressed in the cell, the kinetics
of viral production and release and whether WT or mutated
variants of A3G is expressed in the cell. To compute p(z), we use
our previously built single-cell model [42], where the A3G-Vif
interaction along with other intracellular events such as production
and degradation of host and viral proteins, and assembly and
release of new virions are described using differential equations.
The value of p(z) is inversely associated with the intracellular A3G
getting encapsulated in the released viral particles, i.e., the higher
the production rate of A3G inside the cell, the lower the value of
p(z). It has been observed that in single-round infectivity assays,
cells infected by A3G(+) viruses produce fewer virions compared to
cells infected by A3G(2) viruses [10]. Parameter c denotes the
reduction in the number of virions released from cells infected by
A3G(+) viruses, i.e., NI (z)({) vs. cNI
(z)
({) in equations (4d) and (4e).
This parameter takes values between 0 and 1. Estimates of c have
been obtained using computational models of in vitro T cell culture
infectivity assays [42]. In the model, it is also assumed that cells
infected by A3G(2) or A3G(+) viruses have the same death rate.
Fig. 3A shows a schematic illustration of Model I. This model
provides a benchmark for the optimum performance that A3G-
SCT can achieve in modulating in vivo HIV replication for given
values of p(z) and c.
The observed reduction in the number of produced viruses from
cells infected by A3G(+) viruses could in fact be explained by
decreased infectivity rate of A3G(+) viruses or decreased level of
virus production in cells infected by A3G(+) viruses (represented by
c in Model I) – or both. To compare the effect of decreased
infectivity rate of A3G(+) viruses with that of decreased level of
virus production in cells infected by A3G(+) viruses, we present a
modified version of Model I, where A3G(+) viruses have reduced
infectivity (represented by g in Model Ib in the supplementary
information) compared to A3G(2) viruses. But when infection
occurs, unlike Model I, the number of viruses released from cells
infected by A3G(+) viruses is the same as that of cells infected by
A3G(2) viruses, i.e., all infected cells have the same burst size. As
we will see later in the results section, the level of reduction in the
reproductive ratio for both Models I and Ib are the same given
that the reduction in infectivity rate of A3G(+) viruses is equal to
the reduction in level of virus production in cells infected by
A3G(+) viruses, i.e., c = g. This suggests that from a modeling point
of view, both of these hypotheses could explain the results of
single-round infectivity assays, where cells infected by A3G(+)
viruses produce fewer virions compared to cells infected by
A3G(2) viruses. However, from a mechanistic point of view, the
encapsulated A3G would be unlikely to have effects on viral entry.
This is because the entry process involves the binding of gp41 and
Table 1. Parameter values used for simulations and calculations.
Parameter (units) Values References Definition
l (cells6ml21/day) 20 [73,85] Production rate of uninfected CD4+ T cells in thymus
dT (day
21) 0.02 [79,85] Death rate of uninfected cells
dI (day
21) 0.39 [86] Death rate of infected cells
k (ml6day21) 2.1161024 Calculated Rate constant for uninfected cells getting infected by free virus
N (virions6day21) 850 [86] Average number of free virus produced by an infected cell
dv (day
21) 23 [77,81] Clearance rate of free virus
p(wt) 0.83 Estimated A3G-free virus release ratio: fraction of A3G(2) viruses released from infected WT
CD4+ T cells
p(+) 1024 to1021 [42] A3G-free virus release ratio: fraction of A3G(2) viruses released from infected A3G-
augmented cells
c 1023 to1022 [42] Reduction in the average number of released virions from cells infected by A3G(+)
viruses
f 0 to 1 Fraction of uninfected CD4+ T cells that overexpress A3G
t .1 Ratio of death rate of infected A3G-augmented cells to death rate of infected WT cells
w .1 Ratio of death rate of cells infected by A3G(+) viruses to death rate of cells infected by
A3G(2) viruses
r 0 to 1 Apoptosis failure rate: fraction of infected A3G-augmented cells that escape
apoptosis
R0 20 [86–88] Basic reproductive ratio (output): number of new infections arising from a single
infected cell when almost all the other cells are uninfected.
s Varies Calculated Reduction factor (output): reduction in the basic reproductive ratio resulting from
A3G-SCT
doi:10.1371/journal.pone.0063984.t001
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gp120 on the viral envelope to CD4 and chemokine coreceptors
on the T cell surface, whereas during fusion and entry, A3G is
inside the viral capsid and does not interact with the proteins on
the viral envelope. Therefore, viral entry and infectivity rate
constant are assumed to be the same for both types of virus. On
the other hand, A3G inhibits several steps during integration and
reverse transcription, resulting in production of many nonfunc-
tional viral particles, i.e., reduction in the number of functional
viruses released from the cells infected by A3G(+) viruses.
Figure 2. The basic HIV model: schematic diagram and
simulations. (A) The model consists of three entities: Free viruses,
‘‘uninfected’’ and ‘‘infected’’ CD4+ T cells. Before infection, only
uninfected cells are present with the production rate of l and the
death rate of dT . In the model, infection occurs by introducing an initial
amount of viruses to the body. Free viruses infect uninfected cells and
give rise to infected cells with k representing infectivity rate constant.
Infected cells die at a rate of dI ; before death, these cells produce and
release N new free virions per day. The in vivo clearance rate of viruses
is denoted by dV . (B) The basic reproductive ratio, R0, is defined as the
number of new infections that arise from a single infected cell when
almost all the other cells are uninfected. This important metric
determines whether the infection spreads (R0.1) or dies out (R0,1)
in the body. In the numerical simulation, R0 = 20 initially and a
hypothetical treatment is administered on day 100 which reduces the
value of reproductive ratio by s = 5, 15, 20, 30, and ‘. Although s = ‘
results in the fastest decline in the viral load, the gap between curves
associated with s = 30 and ‘ is small.
doi:10.1371/journal.pone.0063984.g002
Figure 3. Schematic diagram of the extended models of HIV
infection for WT and A3G-augmented cells. Submodels (A) and (B)
show schematic diagrams of HIV infection in A3G-augmented and WT
cells, represented by dark and light blue large circles, respectively. In all
the submodels, HIV infection occurs by a mixed population of A3G(+)
and A3G(2) viruses, represented by dark and light red small circles,
respectively. Large circles with a small circle inside them represent
infected cells with the color of large and small circles demonstrating the
type of cell and the type virus, which caused the infection. Submodel
(C) shows an extended model drawn in (A), where the apoptosis
pathway is activated in A3G-augmented cells upon their infection. The
deformed blue shapes represent infected cells that have undergone
apoptosis. Parameters p(z) and p(wt) denote the fraction A3G(2) viruses
released from infected A3G-augmented and WT cells, respectively. The
reduction in the number of released viruses from cells infected by
A3G(+) viruses is denoted by c. The failure rate of the apoptosis
pathway in (C) is represented by r. Model I is solely described by
submodel (A) while Models IIa, IIb, and IIc consist of submodels in (A)
and (B). Model III is comprised of submodels in (B) and (C).
doi:10.1371/journal.pone.0063984.g003
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Model IIa: The Basic HIV Model for WT and A3G-
Augmented Cells
We next take into account that it may not be possible to
transfect all the CD34+ stem cells and therefore not all the CD4+
T cells would overexpress A3G. Therefore, we extend Model I to
include two subpopulations of uninfected cells: A3G-augmented
cells that overexpress A3G and WT cells that express A3G at
normal levels. Initial infection occurs with a certain amount of
A3G(2) viruses. These viruses can infect both WT and A3G-
augmented cells. WT CD4+ T cells express A3G at low levels such
that Vif can inhibit most of the A3G encapsulation into virions.
When WT cells become infected they produce mostly A3G(2)
virions and less A3G(+) virions, i.e., p(wt) takes high values in the
range [0, 1] (Fig. S1 and Table S1 in Method S1, and [89]). In
contrast, infected A3G-augmented cells produce a higher fraction
of A3G(2) and a lower fraction of A3G(+) virions, i.e., p(z)vp(wt).
The superscript on p denotes whether it is a property of WT or
A3G-augmented cells. The newly released A3G(+) viruses will
similarly infect both WT and A3G-augmented cells. But these
infected cells produce fewer virions. Note that WT cells even after
infection by A3G(+) viruses still produce more A3G(2) virions








































































Where the concentration of A3G-augmented and WT cells are
denoted by T (z) and T (wt), respectively. Parameter f represents
the fraction of uninfected A3G-augmented cells. In this model





represent the concentration of A3G-augmented cells that are
infected by A3G(2) and A3G(+) viruses, respectively. Similarly,





(z) , respectively. In general, for I variables,
superscripts represent whether infected cells are WT or A3G-
augmented, while subscripts denote what type of virus is the cause
of infection. The infectivity rate constant is assumed to be the same
for all virus-cell pairs. All the infected cells have the same death
rate. As described, Model IIa has two submodels describing HIV
infection in A3G-augmented and WT cells, drawn in Figs. 3A and
3B, respectively. The purpose of this model is to investigate what
percentage of the cells must overexpress A3G to block in vivo viral
replication.
Model IIb: The Basic HIV Model for WT and A3G-
Augmented Cells with Lower Death Rates for Infected
A3G-Augmented Cells
As mentioned above, A3G(+) viruses are mostly produced by
infected A3G-augmented cells. These viruses are considered to be
less harmful than A3G(2) viruses. This is because they cause the
infected cells to produce fewer virions than do A3G(2) viruses.
Therefore, it can be hypothesized that if infected A3G-augmented
cells, as the main source for producing A3G(+) viruses, live longer
(die more slowly) compared to infected WT cells, we may achieve
a better performance in blocking replication. We test the effect of
this possible difference in cell lifespan by customizing A3G-
augmented cells to have a lower death rate than WT cells after
they get infected. To change the death rate of infected WT and
A3G-augmented cells in Model IIa, we only need to replace













































I represent the death rate of infected A3G-
augmented and WT cells, respectively. Similar to our notations for
I variables, superscripts on d parameters denote whether infected
cells whose death rate is represented are WT or A3G-augmented.
Note that d
(wt)
I is the same as dI defined in the basic model of HIV
infection; however, d
(z)
I takes smaller values than dI .
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Model IIc: The Basic HIV Model for WT and A3G-
Augmented Cells with Lower Death Rates for Cells
Infected by A3G(+) Viruses
After infection, A3G(+) viruses cause cells to produce and
release fewer virions than do A3G(2) viruses. Therefore, these
viruses might be considered less toxic for cells and as a result cells
infected by A3G(+) viruses might live longer. An important
question to ask is therefore, how would the efficacy of A3G-SCT
change in a model that has a lower death rate for cells infected by


































Where the death rate of cells infected by A3G(+) and A3G(2)
viruses are denoted by dI(z) and dI({) , respectively. Similar to our
notations for I variables, subscripts on d parameters denote
whether cells whose death rate is represented were infected by
A3G(2) or A3G(+) viruses. Note that dI({) is the same as dI
defined in the basic model of HIV infection; however, dI(z) takes
smaller values than dI .
Model III: The Basic HIV Model for WT and A3G-
Augmented Cells with Auto-Apoptosis Capability
For stem cell transfection, the effector gene, in this study a WT
A3G or a functional A3G variant, can be included in a conditional
gene circuit with an appropriate biosensor (as opposed to under
the control of a constitutive promoter). One such biosensor is the
HIV LTR promoter: the HIV protein Tat binds to the promoter
and initiates expression of the effector gene [90–92]. In this way,
transfected A3G is unexpressed until virus entry is detected, and
only then is anti-HIV protein expression boosted. This provides
on-demand antiviral activity at the cellular level with low potential
for side effects. Other functionalities can also be added to the
circuit to make it more potent against HIV infection. For example,
an additional effector gene can be added to induce activation of
the apoptosis pathway upon infection, causing the infected cell to
die, significantly reducing viral production. Model III as described
by the following differential equations is an extension of Model IIa








































































A3G-augmented cells with apoptosis capability are assumed to
die after infection without producing infectious virions. However,
it is also considered that some inefficiencies may be involved with
this process, suggesting that some A3G-augmented cells can
survive after infection. This is captured by the inefficacy rate r in
equations (8c) and (8d), where r is the fraction of infected A3G-
augmented cells that have escaped auto-apoptosis. Model III
submodels are visualized in Figs. 3B and 3C.
Results
In all the simulations, the initial concentration of uninfected
WT CD4+ T cells is 1000 cells/ml. Without loss of generality, the
concentrations of A3G(+) and A3G(2) viruses are given initial
values of zero and one virions/ml, respectively. A3G-augmented
stem cell therapy (A3G-SCT) is introduced on day 100, long after
the system has reached the steady state. R0 = 20 in our simulations
(Table 1). However, in figures, we also plot the level of reduction
required to block in vivo HIV replication with R0 = 70, a
conservatively high value for the reproductive ratio that might
occur temporarily during the course of infection. This shows the
performance of A3G-SCT in the worst-case scenarios. In Figs. 4A–
B and 5A–L, T
(z)
tot refers to the total concentration of uninfected
















(z) , while in Model I, T
(wt)
tot refers to the
total concentration of uninfected and infected WT CD4+ T cells
before introducing the therapy. We use p(wt) = 0.83 in our
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simulations throughout this paper. The value of p(wt) was
estimated using our previously published model [42] and WT
HIV replication data in A3G-expressing and A3G-knockout cells
[89] (Method S1).
A3G Gene Therapy can Effectively Stop in vivo HIV
Replication
Analyzing Model I at steady state and assuming that the virus
grows and establishes infection, we can derive the reproductive










Where s is the reduction factor. Detailed derivation of equation
(9) can be found in Method S2. Since both p(z) and c take values
between zero and one, the reproductive ratio for Model I is
reduced compared to the reproductive ratio for the basic model of
HIV infection. With 100% of stem cells transfected with A3G and
p(z) = 0.1 (90% of the budded virions from each cell carry A3G),
the therapy fails to reduce R1 to values less than one (R1 = 2.02),
however, it causes a 4.8-fold increase in the concentration of T
cells and a 15.3-fold decrease in the total concentration of viruses
(Fig. 4A). By decreasing p(z), the A3G-free virus release ratio, to
0.01 (increasing the percentage of budded virions carrying A3G to
99%), the therapy successfully eradicates the virus from the body
and the concentration of CD4+ T cells goes back to the initial
concentration of 1000 cells/ml (Fig. 4B, R1 = 0.22).
Fig. 4C shows that A3G-SCT can reduce the basic reproductive
ratio by three orders of magnitude for small values of p(z) and c.
However, in order to reduce the reproductive ratio of 20 and 70 to
less than one, p(z) only needs to take values less than 0.049 and
0.013, respectively when c = 0.001, suggesting the potential of
A3G-SCT to successfully achieve a functional cure for HIV
infection. Note that parameter c plays a limiting role in reducing
the reproductive ratio such that as p(z) goes to zero, the maximum
amount of reduction that can be achieved is 1/c fold. Depicted
curves in Fig. 4C represent the best performance that can be
achieved with this treatment for given values of p(z) and c.
The modified version of Model I assumes that A3G(+) viruses
have reduced infectivity (represented by g in Model Ib in Method
S3) compared to A3G(2) viruses. But, the number of viruses
released from cells infected by A3G(+) viruses is the same as that of
cells infected by A3G(-) viruses. The reproductive ratio for Model
Ib is exactly the same as equation (9) if c is replaced with g
(compare equation (9) with equation (SIb-9) in Method S3). This
suggests that reduction in infectivity rate of A3G(+) viruses has the
same effect on the reproductive ratio as does the reduction in level
of virus production in cells infected by A3G(+) viruses. However,
the later is more relevant from a mechanistic point of view.
Figure 4. Effects of A3G-free virus release ratio on HIV
replication and reproductive ratio in Model I. Infection occurs
on day 0 and A3G-SCT begins on day 100 (Model I assumes that all the
cells overexpress A3G). The impact of the therapy on the total
concentration of viruses and cells is shown for (A) p(z) = 0.1 and (B)
0.01. Light and dark red lines represent V({) and V(z) variables,
respectively, while light and dark blue lines represent T (wt)tot and T
(z)
tot
variables, respectively. The left and right axes show the virus and cell
concentrations. Parameter c is given the value of 0.001. Although (A)
p(z) = 0.1 decreases the viral load and increases the T cell count, it
cannot eradicate the virus (R1 = 2.02). However, (B) p
(z) = 0.01
successfully reduces R1 to 0.22 and the infection dies out. (C) shows
the level of reduction in the reproductive ratio that can be achieved by
A3G-SCT for different values of p(z) and c. The green and black dashed
lines represent the minimum level of reduction needed to stop HIV
replication for R0 = 20 and 70, respectively. Note that from left to right
on the bottom axis, the A3G-free virus release ratio decreases from 1021
to 1024. Simulation results suggest that for small values of p(z) and c,
up to three orders of magnitude reduction can be achieved.
doi:10.1371/journal.pone.0063984.g004
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Blocking Replication Requires High Percentage of A3G-
Augmented Cells
Since complete stem cell transfection may not be feasible,
Model IIa splits CD4+ T cells into two subpopulations of WT and
A3G-augmented cells to evaluate the limitations of imperfect
transfection. Studying the model at steady state (Method S4), we



















R2a is reduced compared to the basic reproductive ratio because
parameters p(z), p(wt), c, and f take values less than one. However,
it takes values greater than R1 for f ,1, suggesting that imperfect
transfection reduces the efficacy of A3G-SCT. The reduction
factor, s, shown in equation (10) can be intuitively calculated from
the reduction factor obtained in Model I. This is because now
there exists two cell subpopulations in the system: A3G-augmented
cells with the reduction factor equal to (p(z)+c(12p(z))); and WT
cells with s = (p(wt)+c(12p(wt))). The total reduction factor is hence
the sum of the reduction factor for each cell subpopulation
multiplied by its fraction in the total population. Given that p(wt)
takes a relatively high value of 0.83, one should note that the
reduction caused by WT cells in the reproductive ratio has a lesser
impact than that of A3G-augmented cells.
Although A3G-SCT with f = 90% (R2a = 1.86) and 94%
(R2a = 1.20) causes 18.2- and 77-fold reduction in viral load
and improves total T cell concentration by 5.2- and 7.8-fold,
respectively, the virus is not eradicated and the infection is still
spread in the body (Figs. 5A and 5B, p(z) = 0.01). Increasing
the percentage of A3G-augmented cells to 99% reduces R2a to
0.38 and causes the HIV infection to die out (Fig. 5C,
p(z) = 0.01).
Reduction in the reproductive ratio in Model IIa is shown for
several values of f in Fig. 6A. For f = 95–99%, A3G stem cell
transfection can reduce the reproductive ratio by a factor of 23.5
to 107.6. Note that as p(z) and c go to zero, the fold reduction in
the reproductive ratio approaches 1/(p(wt)(12f)). Therefore
regardless of how small p(z) and c values are, the percentage of
WT cells will determine the performance of the treatment. Fig. 6A
also shows that large reductions in the reproductive ratio can be
achieved as f approaches 1.
Lower Efficacy is Achieved if Infected A3G-Augmented
Cells Die More Slowly than do Infected WT Cells
Model IIb describes a special case when A3G-augmented CD4+
T cells can live longer after they get infected, resulting in lower
death rates for these cells compared to infected WT cells.
Calculating the reproductive ratio for Model IIb illustrates
whether this strategy is beneficial. Modification of the death rate
of infected A3G-augmented cells results in a minor change in
equation (10). The new reproductive ratio can be written as
(Method S5)
R2b~



























Based on our assumption, t must take values greater than one,
which suggests lower therapeutic performance if infected A3G-
augmented cells live longer than infected WT cells, i.e., R2b.R2a
for t .1.
Figs. 5D–F show that as the value of t increases, the
performance of A3G-SCT diminishes (p(z) = 0.01, f = 99%). For
t = 2, the A3G treatment can still eradicate the virus from the body
(Fig. 5E, R2b = 0.60), but the rate of decline in viral load is slower
than that of t = 1 (Fig. 5D, R2b = 0.38). Nonetheless, eradication is
not possible for t = 5 (Fig. 5F, R2b = 1.25).
As seen in Fig. 6B, the highest reduction in the reproductive
ratio is achieved when t = 1, i.e., when infected A3G-augmented
cells have the same death rate as infected WT cells. Also as p(z)
decreases, the gap between the performance of A3G-SCT with
t = 1 and that of therapy with t.1 decreases, meaning that for
small values of p(z), the importance of difference between death
rate of infected A3G-augmented and WT cells is less significant.
Lower Efficacy is Achieved if Cells Infected by A3G(+)
Viruses Die More Slowly than do Cells Infected by A3G(2)
Viruses
Model IIc focuses on a scenario where A3G(+) viruses are
assumed to be less toxic. This is because they cause the infected
cells to produce fewer virions than do A3G(2) viruses. Therefore,
cells infected by A3G(+) viruses may live longer after getting
infected, i.e., they have a lower death rate than that of cells
infected by A3G(2) viruses. By calculating the equilibrium point























Since w is assumed to be greater than one, the performance of
A3G-SCT is degraded compared to Model IIa (R2c.R2a for w
.1). However, the effect of w on the performance of A3G-SCT is
less severe than that of t in Model IIb presented in the previous
section; for f $50%, c = 0.001 and t = w .1, we always have
R2c,R2b, unless p
(z) .1.761024. This can be seen by comparing
Figs. 6B and 6C. In order to reduce the reproductive ratio from 70
to less than one with f = 99.9%, the A3G-free virus release ratio,
needs to be decreased by 1.1 or 1.5-fold when w goes from 1 to 2
or 5, respectively (Fig. 6C). This shows that w has a mild effect on
the performance. In contrast, these numbers are 2.2- and 7.4-fold
when t goes from 1 to 2 or 5, respectively (Fig. 6B).
Comparing Figs. 5G–I, we observe that the efficacy of A3G-
SCT decreases as the value of w increases (p(z) = 0.01, f = 99%).
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Figure 5. Effects of percentage of transfected cells, death rate ratios, and auto-apoptosis failure rate on HIV replication in Models
IIa, IIb, IIc, and III. In all simulations, infection occurs on day 0 and A3G-SCT begins on day 100. In all the subfigures, light and dark red lines




tot variables, respectively. The left and right axes
show the virus and cell concentrations. Parameter c is given the value of 0.001. f = 99% for all the subfigures except (A) and (B) where f = 90% and
94%, respectively. For the first three rows, p(z) = 0.01 (Models IIa, IIb, and IIc), while it is set to 0.1 for the last row (Model III). (A–C, R2a = 1.86, 1.2, and
0.38) simulation results for Model IIa suggest that high percentage of A3G-augmented cells is required to stop in vivo HIV replication. (D–F, R2b = 0.38,
0.6, and 1.25) Model IIb assumes lower death rates for infected A3G-augmented cells compared to infected WT cells, i.e., t .1. Simulation results
suggest that the efficacy of the therapy is degraded as the value of t increases. (G–I, R2c = 0.38, 0.46, and 0.66) A3G(+) viruses are assumed to be less
toxic in Model IIc. Therefore, cells infected by these viruses die more slowly compared to cells infected by A3G(2) viruses, i.e., w .1. Model IIc
predicts that lower death rates for cells infected by A3G(+) viruses have a diminishing effect on the performance of the therapy. (J–L, R3 = 2.16, 0.87,
and 0.37) In Model III, cells are equipped with an additional gene circuit that activates apoptosis pathway upon infection; however, the circuit has a
failure rate of r. Simulation results indicate that providing cells with this additional gene circuit enhances the performance of the therapy and can
reduce the reproductive ratio to values less than one even in cases that the A3G-free virus release ratio does not take very small values.
doi:10.1371/journal.pone.0063984.g005
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For w = 5 (Fig. 5H, R2c = 0.46) and w = 15 (Fig. 5I, R2c = 0.66), the
therapy can eradicate the virus from the body but the rate of
decline in viral load is slower than when w = 1 (Fig. 5G,
R2c = 0.38). By comparing Figs. 5H and 5F, it can be seen that
for the same values of w and t, the rate of decline in virus
concentration is faster, the T cell count is higher, and the viral load
is lower in Model IIc compared to Model IIb.
A3G-Augmented Cells with Auto-Apoptosis Capability
Can Stop Replication more Efficiently
Finally, Model III explores the possibility of enhancing efficacy
of the treatment by co-transfecting stem cells with A3G and a gene
circuit that induces activation of the apoptosis pathway in progeny
CD4+ T cells upon infection by HIV. The gene circuit causes the
cell to die after infection and hence it cannot produce any
infectious virions. However, if the infected cell somehow escapes
the apoptosis pathway, then A3G overexpressed in that cell gets
encapsulated into virions to induce its antiviral activities. The
reproductive ratio for Model III is given by (Method S7)
R3~

















Since r takes values less than one, the reproductive ratio of
Model III is reduced compared to that of Model IIa, suggesting
that a better efficacy can be achieved using co-transfection of stem
cells with A3G and an auto-apoptosis gene circuit. Reduction in
the reproductive ratio for several values or r is shown in Fig. 6D.
For f = 99% and r = 0.1, A3G-SCT reduces the reproductive ratio
of 70 to less than one for any value of p(z) less than 0.059. For
r = 0.01, p(z) should only take values less than 0.60 to be able to
eradicate the virus from the body. This greatly relaxes the pressure
on parameter p(z), the A3G-free virus release ratio, to take values
as small as 0.005 for r = 1 to eradicate the virus, suggesting that
using this therapy A3G or its variants can be overexpressed at
much lower concentrations, and still be effective in blocking HIV
Figure 6. Effects of percentage of transfected cells, death rate ratios, and auto-apoptosis failure rate on reproductive ratio in
Models IIa, IIb, IIc, and III. The level of reduction in the reproductive ratio that can be achieved by A3G-SCT for different values of p(z) is shown for
each model. In all the subfigures, the green and black dashed lines represent the minimum level of reduction needed to stop HIV replication for
R0 = 20 and 70, respectively. Note that from left to right on the bottom axis, the A3G-free virus release ratio decreases from 10
21 to 1024. Parameter c
is given the value of 0.001. (A) Model IIa suggests that f = 95% is required to block HIV replication for R0 = 20. Higher values of f are needed to block
HIV replication for larger values of R0. (B) Simulation results of Model IIb predict that the performance of the therapy will be degraded if infected A3G-
augmented cells die more slowly compared to infected WT cells, i.e., when t .1. (C) Model IIc also suggests that the therapy achieves lower efficacy if
cells infected by A3G(+) viruses die more slowly than cells infected by A3G(2) viruses, i.e., when w .1. However, the performance degradation is less
severe than that of Model IIb. (D) Finally, Model III indicates that A3G-SCT can achieve better efficacy if infected A3G-augmented cells activate
apoptosis pathway upon their infection.
doi:10.1371/journal.pone.0063984.g006
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replication. Note that the improvement in the performance of
therapy becomes less significant for small values of p(z) (Fig. 6D).
For f = 99% and p(z) = 0.1, when r = 1, i.e., the apoptosis gene
circuit fails all the time, the treatment reduces the viral load but
cannot eradicate the virus from the body (Fig. 5J, R3 = 2.16). As r
decreases to 0.35 (the apoptosis gene circuit works 65% of the
time), the treatment can successfully eradicate the virus and the
infection goes away (Fig. 5K, R3 = 0.87). For a smaller value of r in
Fig. 5L while f = 99% and p(z) = 0.1 (R3 = 0.37), the rate of decline
in viral load is even faster than the case of f = 99% and p(z) = 0.01
in Fig. 5C (R1 = 0.38).
A3GDVif Outperforms A3G in Blocking in vivo HIV
Replication
Using the results of our previously published single-cell model
[42], we study the effects of A3G and A3GDVif (an A3G variant
that does not bind Vif such as A3G/F126–129 [43] and
D128KA3G [44]) overexpression on the reproductive ratio.
Fig. 7A shows the reduction in the reproductive ratio achieved
in Model IIa versus the production rate of A3G and A3GDVif. The
APOBEC production rate in Fig. 7 is in addition to the normal
level of A3G production in WT cells. For f = 99%, in order to
reduce the reproductive ratio of 70 to values less than one, the
production rate of A3G should be at least 26 mM/hr while this
number is 0.252 mM/hr for A3GDVif. Analogously, a large gap is
seen between red (A3G) and blue (A3GDVif) curves for other values
of f, suggesting that nearly two orders of magnitude lower
production rate of A3GDVif is required to achieve the same efficacy
as that of A3G. Simulation results for Model III show that as r
decreases, the gap between red (A3G) and blue (A3GDVif) curves
widens (Fig. 7B, f = 99%). For r = 1, in order to reduce the
reproductive ratio of 70 to one, A3GDVif production rate is 103-
fold lower than that of A3G; this number is 331-fold lower for
r = 0.01. Note that for all the curves in both Figs. 7A and 7B, the
reduction factor does not decrease further after a certain
production rate. This is because the percentage of WT cells,
12f, determines the maximum achievable performance of the
treatment, regardless of how much A3G or A3GDVif is overex-
pressed.
Impact of Mixed Levels of A3G Overexpression on the
Performance of A3G-SCT
In Models I, II and III, it is assumed that cells are either WT
(expressing A3G at normal levels) or A3G-augmented (overex-
pressing A3G at high levels). However, stem cell transfection is not
an all-or-none phenomenon, i.e., after the transfection, some of
the progeny CD4+ T cells overexpress A3G at high levels while
others may express A3G at lower levels. Therefore, it is
noteworthy to evaluate the performance of A3G-SCT when all
CD4+ T cells express A3G higher than WT cells, but the
overexpression can be either low or high. Model IV (defined in
Method S8) gives insights into how the performance of the therapy
would change in this scenario. T (zlo) and T (zhi) represent two
subpopulations of cells overexpressing A3G at low and high levels,
respectively. We assume that p(zhi),p(zlo),p(wt). Similar to
Model IIa, the reproductive ratio for Model IV can be



















As seen in Fig. 8, for f = 90% and p(zhi) = 0.001, the other 10%
of the cells that overexpress A3G at low levels need to have p(zlo)
taking values less than 0.48 in order for A3G-SCT to reduce R0
from 20 to one, i.e., only 52% of the viruses released from these
cells must carry A3G for a successful therapy. Note that
p(wt) = 0.83, hence 17% of viruses released from WT infected
cells are already A3G(+). To achieve p(zlo) = 0.48, production rate
of transfected A3G can be 119-fold lower than that of cells
expressing A3G at high levels. Increasing p(zhi) to 0.01 while
keeping f unchanged results in p(zlo) = 0.40 to have a reduction
factor equal to 20. For p(zhi) = 0.01, when f decreases to 50%, i.e.,
the maximum achievable reduction in the reproductive ratio is
Figure 7. Effects of A3G and A3GDVif overexpression on reproductive ratio in Models IIa and III. The level of reduction in the
reproductive ratio that can be achieved by overexpression of A3G (red) and A3GDVif (blue) is shown. In the two subfigures, the green and black
dashed lines represent the minimum level of reduction needed to stop HIV replication for R0 = 20 and 70, respectively. Parameter c is given the value
of 0.001. (A) Simulation results for Model IIa show that almost two orders of magnitude lower production of A3GDVif compared to that of A3G is
required to achieve the same performance. (B) Model III predicts that by decreasing the apoptosis failure rate, lower production rate of A3G and
A3GDVif is required to stop in vivo HIV replication.
doi:10.1371/journal.pone.0063984.g007
Modeling of APOBEC3G-Augmented Stem Cell Therapy
PLOS ONE | www.plosone.org 12 May 2013 | Volume 8 | Issue 5 | e63984
only 2.4-fold in Model IIa, the therapy can cause 20-fold reduction
only if p(zlo) takes values less than 0.09 (Fig. 8).
Discussion
Despite decades of research, 33 million people live with HIV;
2.6 million people are infected annually, with 1.8 million fatalities
[93]. Current leading-edge treatment regimens such as highly
active antiretroviral therapy (HAART) ensure that millions of
people with HIV lead normal lives, and prevent millions of
additional infections by reducing infectivity. However, HAART is
expensive, is not a cure, and only a fraction of HIV sufferers
worldwide receive it. There remains a critical need for new
therapies, especially cures. Cures are preferable because they can
eliminate long-term maintenance costs and issues of adherence to
long-term regimens.
The idea of gene therapy and stem cell transfection has recently
renewed hope to achieve a functional cure for HIV. The reported
cure of the ‘‘Berlin Patient’’ was achieved through transplantation
of hematopoietic stem cells from a donor with two key
characteristics: (a) donor was tissue matched for transplantation;
(b) donor had a genetic mutation that conferred resistance to HIV
[69–71]. Finding such a donor would be difficult in general, but
matched donor stem cells could be augmented, to provide the
HIV-resistance by inserting genes or gene networks into those cells
before transplantation. Small molecules (such as HAART drugs)
cannot be encoded, but overexpression of endogenous anti-HIV
proteins such as APOBEC3G, which can efficiently inhibit viral
reproduction, is possible; alternatively or in addition, encoding a
pro-apoptotic stimulus would induce HIV-infected CD4+ T cells
to die, shortening lifespan and limiting HIV production. Gene
therapy has the potential to counter problems associated with
current anti-HIV treatments such as drug side effects, patient
adherence, and emergence of drug resistant viruses. For some
patients, multiple rounds of low adherence and viral resistance can
lead to exhaustion of all antiviral regiments. Gene therapy can be
promising in these cases; however, in order for it to become a
standard of care in treating HIV, issues such as safety and
persistence of genetically modified cells in the body must be
addressed.
Here, we developed mathematical models extending the basic
model of in vivo HIV infection to describe the impacts that delivery
of stem cells transfected with wild type A3G or its variants can
have on HIV replication. A key novel feature of this work is the
incorporation of previously developed biologically validated model
of A3G-Vif interactions in a single cell [42] into the established
model of in vivo HIV infection [73–78]. Our models can be
generalized to describe and simulate other anti-HIV therapies.
Two crucial parameters of these models are p and c. In the general
form, parameter p is the fraction of released viruses from a single
cell that are unaffected by a drug, an anti-HIV protein, or a
restriction factor. On the other hand, parameter c is the reduction
in the number of viruses released from cells infected by affected
viruses. Knowing p and c for a restriction factor, we can calculate
the efficacy of the therapy.
In our simulations, A3G-augmented stem cell therapy (A3G-
SCT) is introduced on day 100 after initial infection by changing
the production of uninfected CD4+ T cells in thymus to generate
both WT and A3G-augmented CD4+ T cells with the ratio of 1-
f:f. In reality, for stem-cell based gene therapy, CD34+ stem cells
would be mobilized using granulocyte colony stimulating factor
(GCSF) and harvested from the blood for ex vivo gene modifica-
tions. Patients may or may not undergo myeloablative condition-
ing. This procedure is performed prior to bone marrow
transplantation using chemotherapy or total body irradiation with
the purpose of killing all the stem cells and suppressing the
immune response. This in turn leaves the body prone to infections
but reduces the risk of graft-versus-host disease. Finally, transfected
stem cells are reinfused back into patients. After transplantation,
these cells differentiate into cell types such as CD4+ T cells and
macrophages that are now able to overexpress anti-HIV genes. All
these would result in temporary changes in the values of the system
parameters such as production and death rates of CD4+ T cells.
However, several weeks after bone marrow transplantation, stem
cells and their progenies are sufficiently expanded to restore the
immune system and thus we assume that the system parameters
take on values similar to those pre-therapy. Therefore, in this
paper, we focus on the steady state response rather than the
transient response immediately after A3G-SCT to study the
impact of therapy on modulating in vivo HIV replication.
Model I assumes that all CD34+ stem cells in the body are
transfected with A3G or one of its variants. The results for this
model demonstrate that A3G-SCT can reduce the reproductive
ratio to values less than one for sufficiently small values of p(z),
i.e., the concentration of A3G or its variants in HIV-producing
cells must be high enough such that it gets encapsulated in most
viruses. In the next model, it is assumed that a fraction of stem cells
remain untransfected. Model IIa describes the viral dynamics in a
mixed population of A3G-augmented and WT CD4+ T cells and
predicts that the percentage of stem cells transfected with A3G or
its variants must be 95% or higher for the therapy to be able to
successfully stop in vivo HIV replication when the pre-therapy
reproductive ratio is 20. This critical result suggests that A3G-SCT
can be an effective functional cure for HIV infection and would
provide successful results in most clinical settings where R0 takes
values in the range of 10 to 20 [86–88]. Note that the value of f can
be affected by two major factors: efficiency of stem cell transfection
with A3G or its variants; and performance of bone marrow
transplantation. Viral vectors can achieve high transfection
Figure 8. Effects of p(zlo), A3G-free virus release ratio, on
reproductive ratio. The level of reduction in the reproductive ratio
that can be achieved by A3G-SCT for different values of p(zlo) is shown
when p(zhi) = 0.001 (red) and 0.01 (blue). In our simulations,
p(zhi),p(zlo),p(wt). The green and black horizontal dashed lines
represent the minimum level of reduction needed to stop HIV
replication for R0 = 20 and 70, respectively. Note that from left to right
on the bottom axis, p(zlo) decreases from 0.83 to 1023. Parameter c is
given the value of 0.001.
doi:10.1371/journal.pone.0063984.g008
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efficiencies but they raise safety concerns. On the other hand, non-
viral delivery systems such as biomaterials are considered to be safe
but further research and optimizations are needed to improve their
efficiencies. Selection of cells transfected ex vivo should lead to high
incorporation. In terms of bone marrow transplantation, multiple
rounds of reinfusion of CD34+ stem cells may be required in order
to establish a high ratio of stem cells that overexpress A3G. This is
crucial because the maximum achievable reduction by A3G-SCT is
limited by the fraction of WT CD4+ T cells in the body.
Model IIb describes a hypothetical scenario, where infected A3G-
augmented cells die more slowly (while the number of released
viruses from infected cells per day remains unchanged) compared to
infected WT cells. One might expect that the extra condition on
infected A3G-augmented cells could change the balance of A3G(2)
and A3G(+) viruses at steady state such that the reproductive ratio
would be reduced more efficiently. However, the model predicts
that having infected A3G-augmented cells live longer leads to lower
performances. This unexpected result can be explained if we look at
the two subpopulations of target cells. Since there is no interaction/
feedback between the two subpopulations, WT and A3G-
augmented cells appear to act as isolated subsystems. Therefore,
the kinetics of WT subpopulation of cells is untouched, while
infected A3G-augmented cells live longer and produce more virions
compared to the previous case represented in Model IIa, resulting in
a lower decrease in the reproductive ratio.
As mentioned, A3G(+) viruses are considered to be less harmful
than A3G(2) viruses. Model IIc predicts that the performance of the
therapy will be diminished if cells infected by A3G(+) viruses have a
lower death rate than that of cells infected by A3G(2) viruses. Similar
to Model IIb, in order to understand this result, we have to take into
account that although cells infected by A3G(2) viruses are
unchanged, other cells infected by A3G(+) viruses live longer and
release more virions. Therefore, the reduction in the reproductive
ratio is lower compared to Model IIa, resulting in a lower
performance. In the literature, we have not found in vitro measure-
ments of death rates for cells infected by A3G(+) viruses. Therefore
further studies can clarify whether cells infected by A3G(+) viruses
indeed live longer, though the model suggests that the impact of lower
death rates for cells infected by A3G(+) viruses is not severe (Fig. 6C).
Effective gene therapy against HIV will likely require a
combination of anti-HIV mechanisms. Therefore, in addition to
transfecting stem cells with A3G, other gene circuits can also be
employed that may improve the performance of the therapy. Model
III focuses on a case where stem cells are co-transfected with A3G
and an auto-apoptosis gene circuit. Simulation results of Model III
demonstrate that the addition of the auto-apoptosis gene circuit
eases the requirement to have very small values for p(z) to achieve
efficacy. This is an important result because it shows that the auto-
apoptosis gene circuit can be beneficial in cases where overexpres-
sion of A3G or its variants is toxic or not desirable for some reasons.
Model IV relaxes the assumption of all-or none transfection and
studies the performance of A3G-SCT when all stem cells are
transfected but progeny CD4+ T cells overexpress A3G at varying
levels. The model predicts that the performance of A3G-SCT can
be significantly improved if cells that overexpress A3G at low levels
have somewhat higher A3G production rates than WT cells.
In our model, parameters p(z) and p(wt), termed A3G-free virus
release ratio, create an interface between the previously built
single-cell model of A3G-Vif interactions [42] and the in vivo
models of HIV infection described in this work. The A3G-free
virus release ratio is dose-dependent and directly measures the
capability of WT A3G or its variants to get encapsulated into
released virions. Therefore, it effectively avoids the necessity of
taking into account the concentration of anti-HIV proteins in
building the in vivo models. Having simplified the model, the A3G-
free virus release ratio does not shed light on how much protein
production is needed to achieve the required reduction in the
reproductive ratio. Therefore, integrating the single-cell model
results into the in vivo models of HIV infection helps us evaluate
the required production rate of A3G and A3GDVif (a vif resistant
A3G by a single amino acid mutation [43,44]) to stop HIV
replication. Simulation results suggest that the production rate of
A3GDVif can be nearly two orders of magnitude lower than that of
A3G to achieve the same performance, suggesting that A3GDVif
has great potential to be used in gene therapy [72]. This can be
useful in cases where overexpression of A3G is toxic to cells. Other
therapeutic approaches such as using high-affinity antibodies that
bind to Vif [94] or blocking Vif dimerization by small peptides
[95] have been suggested in the literature. One should note that
both of these approaches attempt to inhibit Vif binding to A3G
and hence maximize the efficacy of A3G encapsulation into
virions. But the impact of these strategies is limited by the amount
of A3G that is expressed in cells. In other words, these molecules
cannot reduce the A3G-free virus release ratio sufficiently unless
A3G is also overexpressed. In addition, they would not have any
effect on the performance of A3GDVif, because this protein is a
variant of A3G that does not bind to Vif in the first place. One
potential obstacle in using A3GDVif against HIV infection is the
high mutation rate of the virus. HIV evolves rapidly and it could
mutate Vif protein to restore its ability to bind A3GDVif and to
suppress anti-HIV activities of this restriction factor. In order to
address this issue, similar to the rationale of HAART, other anti-
HIV genes should be combined with A3GDVif to provide several
independent layers of protection against HIV infection, and hence
reduce the chance of viral escape [72].
Although more studies need to be done on in vivo antiviral
effects of A3G, our models suggest that A3G and its variants hold
great promise to be used in stem cell-based anti-HIV gene therapy
clinical trials. Our work presented here takes a computational
approach to give insights into the logistics of a successful A3G-
SCT. Using the viral dynamics of each infected individual, we
could also personalize the therapy to be highly effective. A3G-
SCT may be an option for HIV patients undergoing bone marrow
transplantation due to other complications such as AIDS-related
lymphoma.
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